John McManus - Aeolus Pharmaceuticl CEO and Pres
| AOLS Stock | USD 0.0001 0.00 0.00% |
CEO
Mr. John L. McManus is President, Chief Executive Officer of Aeolus Pharmaceuticals Inc. Mr. McManus began as a consultant to Aeolus in June 2005 as President. He became employed as our President and Chief Operating Officer in July 2006 and was appointed President and Chief Executive Officer in March 2007. Mr. McManus, who received his degree in business administration from the University of Southern California in 1986, is the founder and president of McManus Financial Consultants, Inc., which provides strategic, financial and investor relations advice to senior managements and boards of directors of public companies, including advice on mergers and acquisitions. These companies have a combined value of over 25 billion. He has served as president of MFC since 1997. In addition, Mr. McManus previously served as Vice President, Finance and Strategic Planning to Spectrum Pharmaceuticals, Inc., where he had primary responsibility for restructuring Spectrums operations and finances, including the design of strategic and financial plans to enhance Spectrums corporate focus, and leading the successful implementation of these plans and relisting of the Company on NASDAQ. The implementation of these plans led to an increase in Spectrums market value from 1 million to more than 125 million at the time of Mr. McManus departure. since 2011.
| Age | 59 |
| Tenure | 13 years |
| Phone | 949-481-9825 |
| Web | https://www.aeoluspharma.com |
Aeolus Pharmaceuticl Management Efficiency
The company has return on total asset (ROA) of (0.903) % which means that it has lost $0.903 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8643) %, meaning that it created substantial loss on money invested by shareholders. Aeolus Pharmaceuticl's management efficiency ratios could be used to measure how well Aeolus Pharmaceuticl manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | CEO Age | ||
| LLM JD | Tempest Therapeutics | 54 | |
| Dietrich MBA | DiaMedica Therapeutics | 53 | |
| Nevan JD | Rezolute | 57 | |
| Jon Congleton | Mineralys Therapeutics, Common | 61 | |
| Paul Wagner | Forte Biosciences | 54 | |
Management Performance
| Return On Equity | -1.86 | |||
| Return On Asset | -0.9 |
Aeolus Pharmaceuticl Leadership Team
Elected by the shareholders, the Aeolus Pharmaceuticl's board of directors comprises two types of representatives: Aeolus Pharmaceuticl inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aeolus. The board's role is to monitor Aeolus Pharmaceuticl's management team and ensure that shareholders' interests are well served. Aeolus Pharmaceuticl's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aeolus Pharmaceuticl's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Stanley, VP Operations | ||
| John McManus, CEO and Pres |
Aeolus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Aeolus Pharmaceuticl a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.86 | |||
| Return On Asset | -0.9 | |||
| Operating Margin | (5.31) % | |||
| Current Valuation | 167.29 K | |||
| Shares Outstanding | 152.09 M | |||
| Price To Earning | (2.37) X | |||
| Price To Book | 0.81 X | |||
| Price To Sales | 0.22 X | |||
| Revenue | 2.08 M | |||
| Gross Profit | (805 K) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aeolus Pink Sheet Analysis
When running Aeolus Pharmaceuticl's price analysis, check to measure Aeolus Pharmaceuticl's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aeolus Pharmaceuticl is operating at the current time. Most of Aeolus Pharmaceuticl's value examination focuses on studying past and present price action to predict the probability of Aeolus Pharmaceuticl's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aeolus Pharmaceuticl's price. Additionally, you may evaluate how the addition of Aeolus Pharmaceuticl to your portfolios can decrease your overall portfolio volatility.